H1512

Haloperidol

≥98% (TLC), powder, dopamine receptor antagonist

• Sinônimo(s): 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone, 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone, 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone
• Fórmula empírica (Notação de Hill): C₂₁H₂₃ClFNO₂
• Número CAS: 52-86-8
• Peso molecular: 375.86
• Número CE: 200-155-6
• Número MDL: MFCD00051423
• Código UNSPSC: 12352200
• ID de substância PubChem: 24277917
• NACRES: NA.77

Propriedades

• Nome do produto: Haloperidol, powder
• Formulário: powder
• Nível de qualidade: 200
• cor: white
• solubilidade: 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.39 mg/mL; 0.1 M HCl: 3 mg/mL; DMSO: soluble; H₂O: insoluble; ethanol: soluble
• originador: Johnson & Johnson
• cadeia de caracteres SMILES: OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3
• InChI: 1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
• chave InChI: LNEPOXFFQSENCJ-UHFFFAOYSA-N
• Informações sobre genes: human ... ABCB1(5243) , ADRA1A(148) , ADRA2A(150) , ADRA2C(152) , CHRM1(1128) , DRD2(1813) , DRD3(1814) , DRD4(1815) , EBP(10682) , HRH1(3269) , HTR2A(3356) , HTR2C(3358) , HTR7(3363) , KCNH1(3756) , KCNH2(3757) , PRNP(5621) ; rat ... Adra1a(29412) , Adra2a(25083) , Chrm1(25229) , Chrm2(81645) , Drd1a(24316) , Drd2(24318) , Drd3(29238) , Drd4(25432) , Hrh1(24448) , Htr1a(24473) , Htr1b(25075) , Htr2a(29595) , Htr2c(25187) , Oprs1(29336) , Slc6a3(24898) , Slc6a4(25553)

Descrição

Aplicação

Haloperidol has been used:

• in ethanol to serves as an inhibitor of Erg2p[1]
• to address the mechanism of haloperidol in ferroptosis using hepatocellular carcinoma cells: Hep G2 and Huh-7 cell lines[2]
• in receptor internalization assay[3]
• as an antipsychotic drug in Dulbecco′s Modified Eagle medium[4]

Ações bioquímicas/fisiológicas

Haloperidol is a butyrophenone antipsychotic. It is also classified as a neuroleptic (powerful tranquilizer). Haloperidol acts as a D2, D3, and D4 dopamine receptor antagonist and thus causes Parkinson′s disorder. It also has a negative effect on the central nervous system.[5]

Características e benefícios

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informações de segurança

• Pictogramas: GHS06,GHS08
• Palavra indicadora: Danger
• Frases de perigo: H301,H315,H317,H319,H335,H361
• Declarações de precaução: P202 - P261 - P280 - P301 + P310 - P302 + P352 - P305 + P351 + P338
• Classificações de perigo: Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
• Órgãos-alvo: Respiratory system
• Código de classe de armazenamento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable